1.      Elinzanetant reduced moderate to severe vasomotor symptoms by 74% at 12 weeks vs 47% with placebo.

2.      Symptom reductions were seen within 1 week and sustained through 1 year.

3.      Patients reported improvements in sleep disturbance and menopause-related quality of life.

4.      Adverse events occurred in 70% with elinzanetant and 61% with placebo, most commonly somnolence, fatigue, and headache. No hepatotoxicity, endometrial abnormalities, or bone loss were observed.

5.      Phase 3 trial, 628 postmenopausal patients, randomized to elinzanetant or placebo across 83 sites.

6.      Underrepresentation of Asian and Pacific Islander patients; not powered for secondary endpoints; patients with recent cancer histories excluded.

Source: JAMA Internal Medicine